GUIDELINES, TIMELINE AND DELIVERABLES
- Diagnose anaphylaxis such that life-saving treatment can be administered more quickly.
- Identify novel ways to minimize reaction severity in those already sensitized to specific allergens or those who experience onset later in life.
- Address the anaphylactic response vs. initial sensitization.
- Uncover new pathways and targets that can be modulated to reduce or alleviate anaphylaxis.
- EAT is not requesting IP ownership; instead, EAT’s grant is structured to participate in the net revenues generated from successfully commercializing any novel idea or invention
- EAT Investment Panelists and the EAT Board of Directors will be the only individuals reviewing all plans in their entirety. All reviewers will be required to sign a non-disclosure agreement upon the request of the applicant.
- Specific funding milestones will be developed and provided to each Finalist
- Grant will fund direct costs, and up to 10% of indirect costs.
- Any individual, organization or institution is eligible to submit
- Finalists may be required to provide additional information between January 2, 2020 and March 1, 2020
- August 1, 2019: Intent to Submit due by 11:59pm EST emailed (or DropBox link sent) to Research@EndAllergiesTogether.com
- October 15, 2019: Final Submission due by 11:59pm EST emailed (or DropBox link sent) to Research@EndAllergiesTogether.com
- Early January, 2020: Finalists announced: All applicants will receive an email on their status from Research@EndAllergiesTogether.com
- Q1 2020 Date TBD: Awards Dinner
1) Intent to Submit Due August 1, 2019. Maximum one page project summary
2) Research and Business Plan Due October 15, 2019. Maximum ten pages, not including Appendix. Must include:
- Title and Team
- Executive Summary
- Project goal(s) and how they specifically address the EAT Grand Challenge
- Scientific Plan and Supporting Evidence
- Detailed description of proposed intervention
- Mechanistic / scientific rational
- Development and approval plan
- Full citation and/or inclusion of supporting data
- Product and Path to Commercialization
- Product profile
- Product safety considerations
- Regulatory strategy
- IP status
- Market analysis
- Stakeholder analysis (doctors, nurses, end users, payers, etc.)
- Financing or corporate strategy (including fund raising, strategic partnerships or licensing)
- Timeline, Key Milestones and Funding Plan
- Investment needed to reach specific key milestones; estimated completion
- Lay out risks and gating factors (recruiting, samples, QC, etc.)
- Disclosure of existing funding sources and staging
- Team Biographies
- Current and pending grants and investments
- Facilities and equipment description
3) Finalists May Be Asked to Provide Additional Information or Answer Clarifying Questions Between January 2, 2020 and March 1, 2020
Questions? Email us at Research@EndAllergiesTogether.com